Close Menu

SACGHS

Leaving a "remarkable record" – and some issues unresolved – SACGHS completes its charter with a flurry of guidances.

The agency's CDRH branch is currently weighing options on regulating lab-developed tests and is considering looking at 'high-risk' tests first.

According to a notice from SACGHS this week, the committee's charter, slated to expire Sept. 23, will not be renewed by HHS Secretary Kathleen Sebelius.

The Secretary's Advisory Committee on Genetics, Health, and Society will disband next month, eight years after its founding. The committee had completed its original task, advising HHS on a number of issues related to genomics.

Acknowledging that a person's clinical, genetic, and environmental information impact the way he or she responds to treatments, the AMA's policy now urges healthcare providers to educate themselves in the discipline.

The HHS committee has formed a task force to consider ways that genomic data-sharing policies do or do not lead to problems that can harm groups, disturb individual privacy, or lead to ethical and legal problems.

The HHS advisory committee on genetics decided yesterday to form a group to consider if medicine is ready for cheaper personal genome sequencing, and if it is ready to be of use to doctors and patients.

Professional development for doctors, consumer outreach for patients, and reimbursement for genetics are among the recommendations in a new SACGHS task force report.

In a request for public input on the scope of its planned voluntary genetic testing registry, NIH indicates that it "anticipates" including tests from direct-to-consumer genomics firms.

A task force is considering advice for HHS to help doctors, industry, and consumers prepare for the personalized medicine era.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.